Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Gastrointestinal and Other Cancers
Sponsor
National Cancer Institute (NCI)
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02134925
This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant
vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous
polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer
over time. Vaccines made from peptides may help the body build an effective immune response
to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence
of adenomatous polyps and may prevent the development of colorectal cancer.
vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous
polyps). Adenomatous polyps are growths in the colon that may develop into colorectal cancer
over time. Vaccines made from peptides may help the body build an effective immune response
to kill polyp cells. MUC1 peptide-poly-ICLC adjuvant vaccine may also prevent the recurrence
of adenomatous polyps and may prevent the development of colorectal cancer.
Intervention
Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline
Condition
Colorectal Adenoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Tubulovillous Adenoma
Investigators
Robert E Schoen